FDAsafety guidance66% confidence
FDA AP — MORPHINE SULFATE (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Hikma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA022195. Sponsor: HIKMA. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: MORPHINE SULFATE.
Supporting Context
- Therapeutic area
- Pain Management · Opioid
- Sub-indication
- Pain
Related signal: FDA Accepts Supplement for Codeine Sulfate by Hikma